Livestock biotechnology meeting, a three-day convention, is set to take place in Kansas City this week with a focus on discussion over global issues through genetically engineered animals. The Biotechnology Industry Organization has sponsored the meeting opening on Wednesday.
The event will have presentations on the use of genetically engineered animals for animal health, human health and food production. Other speakers will speak about the role of scientific innovation in feeding the rising global population. Missouri Agriculture Department Director Jon Hagler is scheduled to give presentation on Friday on the future of agriculture.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) jumped on Tuesday after it unveiled a plan to present a corporate overview at the UBS Global Life Sciences Conference on Thursday, September 20, 2012, at 7:30 a.m. Eastern Time (4:30 a.m. Pacific Time) at the Grand Hyatt New York City.
The stock’s price increased in the last trading session with a previous 52-week high of $13.50. The stock was trading on above-average volume. The stock traded at a volume of 19.34 million shares at a price gain of 7.42%. The share price is now down -4.54% for the past three months. Latest closing price was 8.28% above its 50-day moving average and 6.38% above its 200-day moving average.
Gilead Sciences, Inc. (NASDAQ:GILD) was a top price hitter after analyst Geoff Meacham lifted price target from $70 to $75 and predicted higher sales for a HIV drug, Stribild. While trading at volume higher than average, the stock climbed 1.47% yesterday. Its previous 52-week high was $67.55 and moved up 63.49% over the same period, trading at a volume of 18.58 million. Shares have risen 42.13% over the trailing 6 months. The stock is currently trading 19.08% above its SMA 50 and 34.49% above its SMA 200.
Peregrine Pharmaceuticals (NASDAQ:PPHM) continued to surge as it is set to provide a review at The New York Palace Hotel event in New York, with management conducting meetings on Friday, September 21, 2012. Over the last 12 months, a return on equity of -530.39 percent was realized due to the financial situation and earnings per share reached a value of -$0.47. The stock closed at $4.41, up 0.22 points or 5.25% from previous close and at a distance of 41.03% from 20-day simple moving average.
Dendreon Corporation (NASDAQ:DNDN) moved down -34.08% in this year and its price history showed most recently beta was at 2.42. Over the last 12 months, the percentage change in the price was -54.29%, hitting the highest of $17.04 on Feb 07, 2012 while lowest level in that period was $4.17 on Aug 02, 2012.